Imprimis Pharmaceuticals, Inc. and DPT Labs have entered an agreement under which DPT will supply Imprimis with quantities of its active topical anti-inflammatory drug, Impracor, for Phase III trials. Impracor is the first drug to be developed using Imprimis’s Accudel topical delivery technology. Imprimis Pharmaceuticals, Inc. chief executive officer, Mark L. Baum said, “Imprimis is pleased to have entered into an agreement for manufacturing our active Impracor clinical supplies fro...